Construction, modification and evaluation of apolipoprotein A-I promoter-driven shRNA expression vectors against hTERT

Plasmid

Volumn 65, Issue 1, 2011, Pages 42-50

  Ren, Xueling ^a   Ma, Yue ^a   Xu, Min ^a   Chen, Tingting ^a   Zhang, Zhenzhong ^a   Zhang, Yun ^a  

^a ZHENGZHOU UNIVERSITY   (China)

Author keywords

Apolipoprotein A I; HTERT; RNA polymerase II; RNA polymerase III; ShRNA

Indexed keywords

APOLIPOPROTEIN A1; CIS ACTING ELEMENT; GREEN FLUORESCENT PROTEIN; HAMMERHEAD RIBOZYME; MESSENGER RNA; SHORT HAIRPIN RNA; TELOMERASE REVERSE TRANSCRIPTASE;

ARTICLE; CONTROLLED STUDY; DRUG TARGETING; ENHANCER REGION; ENZYME INHIBITION; EXPRESSION VECTOR; GENE EXPRESSION; GENE THERAPY; HUMAN; HUMAN CELL; LIVER; NUCLEOTIDE SEQUENCE; PLASMID; PROMOTER REGION; TISSUE SPECIFICITY;

5' FLANKING REGION; APOLIPOPROTEIN A-I; BASE SEQUENCE; CELL LINE, TUMOR; GENE EXPRESSION REGULATION; GENE KNOCKDOWN TECHNIQUES; GENETIC TECHNIQUES; GENETIC VECTORS; GREEN FLUORESCENT PROTEINS; HUMANS; MOLECULAR SEQUENCE DATA; PROMOTER REGIONS, GENETIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; RNA POLYMERASE II; RNA, MESSENGER; RNA, SMALL INTERFERING; TELOMERASE; TRANSCRIPTION, GENETIC;

EID: 78650723903     PISSN: 0147619X     EISSN: 10959890     Source Type: Journal    
DOI: 10.1016/j.plasmid.2010.11.001     Document Type: Article

References (30)

1. Arbuthnot P., Thompson L.J. Harnessing the RNA interference pathway to advance treatment and prevention of hepatocellular carcinoma. World J. Gastroenterol. 2008, 14:1670-1681.
2. Chakravarty K., Cassuto H., Reshef L., Hanson R.W. Factors that control the tissue-specific transcription of the gene for phosphoenolpyruvate carboxykinase-C. Crit. Rev. Biochem. Mol. 2005, 40:129-154.
3. Fakhoury J., Nimmo G.A., Autexier C. Harnessing telomerase in cancer therapeutics. Anticancer Agents Med. Chem. 2007, 7:475-483.
4. Fewell G.D., Schmitt K. Vector-based RNAi approaches for stable, inducible and genome-wide screens. Drug Discov. Today 2006, 11:975-982.
5. Fletcher T.M. Telomerase: a potential therapeutic target for cancer. Expert Opin. Ther. Targets 2005, 9:457-469.
6. Gigek C.O., Leal M.F., Silva P.N.O., Lisboa L.C.F., Lima E.M., Calcagno D.Q., Assunpçäo P.P., Burbano R.R., Smith M.A.C. HTERT methylation and expression in gastric cancer. Biomarkers 2009, 14:630-636.
7. Haas M.J., Reinacher D., Li J.P., Wong N.C., Mooradian A.D. Regulation of apoA-I gene expression with acidosis: requirement for a transcriptional repressor. J. Mol. Endocrinol. 2001, 27:43-57.
8. Higuchi K., Law S.W., Hoeg J.M., Schumacher U.K., Meglin N., Brewer H.B. Tissue-specific expression of apolipoprotein A-I (apoA-I) is regulated by the 5'-flanking region of the human apoA-I gene. J. Biol. Chem. 1988, 263:18530-18536.
9. Ido A., Uto H., Moriuchi A., Nagata K., Onaga Y., Onaga M., Hori T., Hirono S., Hayashi K., Tamaoki T., Tsubouchi H. Gene therapy targeting for hepatocellular carcinoma: selective and enhanced suicide gene expression regulated by a hypoxia-inducible enhancer linked to a human α-fetoprotein promoter. Cancer Res. 2001, 61:3016-3021.
10. Kanai F. Transcriptional targeted gene therapy for hepatocellular carcinoma by adenovirus vector. Mol. Biotechnol. 2001, 18:243-250.
11. Kim S.I., Shin D., Lee H., Ahn B.Y., Yoon Y., Kim M. Targeted delivery of siRNA against hepatitis C virus by apolipoprotein A-I-bound cationic liposomes. J. Hepatol. 2009, 50:479-488.
12. Lam P.Y.P., Sia K.C., Khong J.H., Geest B.D., Lim K.S., Ho I.A., Wang G.Y., Miao L., Huynh H., Hui K.M. An efficient and safe herpes simplex virus type 1 amplicon vector for transcriptionally targeted therapy of human hepatocullular carcinomas. Mol. Ther. 2007, 15:1129-1136.
13. Merritt W.M., Bar-Eli M., Sood A.K. The dicey role of dicer: implications for RNAi therapy. Cancer Res. 2010, 70:2571-2574.
14. Papadakis E.D., Nicklin S.A., Baker A.H., White S.J. Promoters and control elements: designing expression cassettes for gene therapy. Curr. Gene Ther. 2004, 4:89-113.
15. Farazi P.A., De Pinho R.A. Hepatocellular carcinoma pathogenesis: from genes to environment. Nat. Rev. Cancer 2006, 6:674-687.
16. Park C.W., Park Y.M., Lee G.T., Lee Y., Woo S., Cha J.Y., Ahn C.W., Cha B.S., Kim K.S., Ahn Y.H., Lee H.C. Targeting of therapeutic gene expression to the liver by using liver-type pyruvate kinase proximal promoter and the SV40 viral enhancer active in multiple cell types. Biochem. Biophys. Res. Commun. 2004, 314:131-137.
17. Rao D.D., Senzer N., Cleary M.A., Nemunaitis J. Comparative assessment of siRNA and shRNA off target effects: what is slowing clinical development. Cancer Gene Ther. 2009, 16:807-809.
18. Reynolds A., Leake D., Scaringe S., Marshall W.S., Khvorova A. Rational siRNA design for RNA interference. Nat. Biotechnol. 2004, 22:326-330.
19. Shi Y.J., Gong J.P., Liu C.A., Li X.H., Mei Y., Mi C., Huo Y.Y. Construction of a targeting adenoviral vector carrying AFP promoter for expressing EGFP gene in AFP-producing hepatocarcinoma cell. World J. Gastroenterol. 2004, 10:186-189.
20. Shinagawa T., Shunsuke I. Generation of Ski-knockdown mice by expressing a long double-strand RNA from an RNA polymerase II promoter. Gene Dev. 2003, 17:1340-1345.
21. Stegmeier F., Hu G., Rickles R.J., Hannon G.J., Elledge S.J. A lentiviral microRNA-based system for single-copy polymerase II-regulated RNA interference in mammalian cells. Proc. Natl. Acad. Sci. USA 2005, 102:13212-13217.
22. Suzuki K., Kelleher A.D. Transcriptional regulation by promoter targeted RNAs. Curr. Top Med. Chem. 2009, 9:1079-1087.
23. Tan E.L., Tan T.M.C., Chow V.T.K., Poh C.L. Enhanced potency and efficacy of 29-mer shRNA in inhibition of Enterovirus 71. Antivir. Res. 2007, 74:9-15.
24. Wang D.S., Dou K.F., Li K.Z., Song Z.S. Enhancement of migration and invasion of hepatoma cells via a Rho GTPase signaling pathway. World J. Gastroenterol. 2004, 10:299-302.
25. Wang L.N., Li Z., Xue Z.G., Xue J.F., Hu Y.J., Zhou Y. Incorporation of prokaryotic enhancer for enhancement of gene expression driven by hTERT promoter. Chin. J. Cancer Prev. Treat. 2006, 13:1125-1130.
26. Wang S.L., Yao H.H., Qin Z.H. Strategies for short hairpin RNA delivery in cancer gene therapy. Expert Opin. Biol. Ther. 2009, 9:1357-1368.
27. Xu Z.L., Mizuguchi H., Ishii-Watabe A., Uchida E., Mayumi T., Hayakawa T. Optimization of transcriptional regulatory elements for constructing plasmid vectors. Gene 2001, 272:149-156.
28. Yonaha M., Proudfoot N.J. Specific transcriptional pausing activates polyadenylation in a coupled in vitro system. Mol. Cell. 1999, 3:593-600.
29. Zhang P.H., Zou L., Tu Z.G. RNAi-hTERT inhibition hepatocellular carcinoma cell proliferation via decreasing telomerase activity. J. Surg. Res. 2006, 131:143-149.
30. Zheng J.N., Pei D.S., Sun F.H., Zhang B.F., Liu X.Y., Gu J.F., Lui Y.H., Hu X.L., Mao L.J., Wen R.M., Liu J.J., Li W. Inhibition of renal cancer cell growth by oncolytic adenovirus armed short hairpin RNA targeting hTERT gene. Cancer Biol. Ther. 2009, 8:84-91.